Patient perceptions of the Raynaud's Condition Score diary provide insight into its performance in clinical trials of Raynaud's phenomenon

Comment on the Article by Denton et al

John D Pauling, Lesley A Saketkoo, Robyn T Domsic

Research output: Contribution to journalLetter

8 Citations (Scopus)
14 Downloads (Pure)

Abstract

The recent report by Denton et al. [1] adds to previous well-designed negative placebo-controlled clinical trials of Raynaud's phenomenon (RP) in systemic sclerosis (SSc). The primary endpoint was the weekly average number of RP attacks, with secondary endpoints including daily RP attack duration and RP severity (the single-item Raynaud's Condition Score [RCS]), that together comprise the RCS diary. The accompanying editorial, provides insightful suppositions of factors contributing to the disappointing performance of the RCS diary in clinical trials [2].

Original languageEnglish
Pages (from-to)973-974
Number of pages2
JournalArthritis & Rheumatology
Volume70
Issue number6
Early online date7 Mar 2018
DOIs
Publication statusPublished - 1 Jun 2018

Fingerprint

Raynaud Disease
Clinical Trials
Systemic Scleroderma
Controlled Clinical Trials
Placebos

Keywords

  • Letter

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Cite this

@article{193494f775f94011a836d43fff10b81f,
title = "Patient perceptions of the Raynaud's Condition Score diary provide insight into its performance in clinical trials of Raynaud's phenomenon: Comment on the Article by Denton et al",
abstract = "The recent report by Denton et al. [1] adds to previous well-designed negative placebo-controlled clinical trials of Raynaud's phenomenon (RP) in systemic sclerosis (SSc). The primary endpoint was the weekly average number of RP attacks, with secondary endpoints including daily RP attack duration and RP severity (the single-item Raynaud's Condition Score [RCS]), that together comprise the RCS diary. The accompanying editorial, provides insightful suppositions of factors contributing to the disappointing performance of the RCS diary in clinical trials [2].",
keywords = "Letter",
author = "Pauling, {John D} and Saketkoo, {Lesley A} and Domsic, {Robyn T}",
note = "This article is protected by copyright. All rights reserved.",
year = "2018",
month = "6",
day = "1",
doi = "10.1002/art.40481",
language = "English",
volume = "70",
pages = "973--974",
journal = "Arthritis & Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Patient perceptions of the Raynaud's Condition Score diary provide insight into its performance in clinical trials of Raynaud's phenomenon

T2 - Comment on the Article by Denton et al

AU - Pauling, John D

AU - Saketkoo, Lesley A

AU - Domsic, Robyn T

N1 - This article is protected by copyright. All rights reserved.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - The recent report by Denton et al. [1] adds to previous well-designed negative placebo-controlled clinical trials of Raynaud's phenomenon (RP) in systemic sclerosis (SSc). The primary endpoint was the weekly average number of RP attacks, with secondary endpoints including daily RP attack duration and RP severity (the single-item Raynaud's Condition Score [RCS]), that together comprise the RCS diary. The accompanying editorial, provides insightful suppositions of factors contributing to the disappointing performance of the RCS diary in clinical trials [2].

AB - The recent report by Denton et al. [1] adds to previous well-designed negative placebo-controlled clinical trials of Raynaud's phenomenon (RP) in systemic sclerosis (SSc). The primary endpoint was the weekly average number of RP attacks, with secondary endpoints including daily RP attack duration and RP severity (the single-item Raynaud's Condition Score [RCS]), that together comprise the RCS diary. The accompanying editorial, provides insightful suppositions of factors contributing to the disappointing performance of the RCS diary in clinical trials [2].

KW - Letter

UR - http://www.scopus.com/inward/record.url?scp=85046033444&partnerID=8YFLogxK

U2 - 10.1002/art.40481

DO - 10.1002/art.40481

M3 - Letter

VL - 70

SP - 973

EP - 974

JO - Arthritis & Rheumatology

JF - Arthritis & Rheumatology

SN - 2326-5191

IS - 6

ER -